Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology)

N/A

Report date: 2024/11/18 20:00:28

Base Information

Drug NameAnti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology)
Drug Alias NameCD19 CAR-T cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionImmunologic cytotoxicityProgrammed death-ligand 1 blockersT lymphocyte replacements +[4] 
TargetsB-lymphocyte antigen CD19Programmed death-ligand 1
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesTianjin Mycure Medical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTianjin Mycure Medical Technology Co Ltd
Active IndicationsN/A
Inactive IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A